Virus-specific CD8+ T cells infiltrate melanoma lesions and retain function independently of PD-1 expression

Journal of Immunology

Volumn 198, Issue 7, 2017, Pages 2979-2988

  Erkes, Dan A ^a   Smith, Corinne J ^a   Wilski, Nicole A ^a   Caldeira Dantas, Sofia ^a,b,c   Mohgbeli, Toktam ^a   Snyder, Christopher M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN; PDCD1 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DRUG EFFICACY; HERPESVIRIDAE; IMMUNE STATUS; IMMUNOTHERAPY; INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NONHUMAN; POXVIRIDAE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; VACCINIA VIRUS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPLICATION; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; HERPES VIRUS INFECTION; IMMUNOLOGY; MUROMEGALOVIRUS; POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; VACCINIA; VIRUS INFECTION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; HERPESVIRIDAE INFECTIONS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUROMEGALOVIRUS; POLYMERASE CHAIN REACTION; PROGRAMMED CELL DEATH 1 RECEPTOR; VACCINIA; VACCINIA VIRUS; VIRUS DISEASES;

EID: 85016274466     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1601064     Document Type: Article

References (49)

1. Hadrup, S., M. Donia, and P. Thor Straten. 2013. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron. 6: 123-133.
2. Gooden, M. J., G. H. de Bock, N. Leffers, T. Daemen, and H. W. Nijman. 2011. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer 105: 93-103.
3. Restifo, N. P., M. E. Dudley, and S. A. Rosenberg. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12: 269-281.
4. Hailemichael, Y., and W. W. Overwijk. 2014. Cancer vaccines: trafficking of tumor-specific T cells to tumor after therapeutic vaccination. Int. J. Biochem. Cell Biol. 53: 46-50.
5. Rosenberg, S. A., and N. P. Restifo. 2015. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348: 62-68.
6. Manzo, T., H. E. Heslop, and C. M. Rooney. 2015. Antigen-specific T cell therapies for cancer. Hum. Mol. Genet. 24(R1): R67-R73.
7. Schuessler, A., D. G. Walker, and R. Khanna. 2014. Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme. Front. Oncol. 4: 275.
8. Rosenberg, S. A., J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17: 4550-4557.
9. Baitsch, L., P. Baumgaertner, E. Devevre, S. K. Raghav, A. Legat, L. Barba, S. Wieckowski, H. Bouzourene, B. Deplancke, P. Romero, et al. 2011. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J. Clin. Invest. 121: 2350-2360.
10. Sakuishi, K., L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. [Published erratum appears in 2011 J. Exp. Med. 208: 1331.] J. Exp. Med. 207: 2187-2194.
11. Fourcade, J., Z. Sun, M. Benallaoua, P. Guillaume, I. F. Luescher, C. Sander, J. M. Kirkwood, V. Kuchroo, and H. M. Zarour. 2010. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207: 2175-2186.
12. Ahmadzadeh, M., L. A. Johnson, B. Heemskerk, J. R.Wunderlich, M. E. Dudley, D. E. White, and S. A. Rosenberg. 2009. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114: 1537-1544.
13. Wherry, E. J. 2011. T cell exhaustion. Nat. Immunol. 12: 492-499.
14. Chen, L., and X. Han. 2015. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125: 3384-3391.
15. Gros, A., P. F. Robbins, X. Yao, Y. F. Li, S. Turcotte, E. Tran, J. R. Wunderlich, A. Mixon, S. Farid, M. E. Dudley, et al. 2014. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124: 2246-2259.
16. Virgin, H. W., E. J. Wherry, and R. Ahmed. 2009. Redefining chronic viral infection. Cell 138: 30-50.
17. Simon, C. O., R. Holtappels, H. M. Tervo, V. Böhm, T. Däubner, S. A. Oehrlein-Karpi, B. Kühnapfel, A. Renzaho, D. Strand, J. Podlech, et al. 2006. CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J. Virol. 80: 10436-10456.
18. Polić, B., H. Hengel, A. Krmpotić, J. Trgovcich, I. Pavić, P. Luccaronin, S. Jonjić, and U. H. Koszinowski. 1998. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 188: 1047-1054.
19. Thompson, E. D., H. L. Enriquez, Y. X. Fu, and V. H. Engelhard. 2010. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J. Exp. Med. 207: 1791-1804.
20. Quinn, M., D. A. Erkes, and C. M. Snyder. 2016. Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector. Immunotherapy 8: 211-221.
21. Dankort, D., D. P. Curley, R. A. Cartlidge, B. Nelson, A. N. Karnezis, W. E. Damsky, Jr., M. J. You, R. A. DePinho, M. McMahon, and M. Bosenberg. 2009. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41: 544-552.
22. Zurbach, K. A., T. Moghbeli, and C. M. Snyder. 2014. Resolving the titer of murine cytomegalovirus by plaque assay using the M2-10B4 cell line and a low viscosity overlay. Virol. J. 11: 71.
23. Turula, H., C. J. Smith, F. Grey, K. A. Zurbach, and C. M. Snyder. 2013. Competition between T cells maintains clonal dominance during memory inflation induced by MCMV. Eur. J. Immunol. 43: 1252-1263.
24. Erkes, D. A., G. Xu, C. Daskalakis, K. A. Zurbach, N. A. Wilski, T. Moghbeli, A. B. Hill, and C. M. Snyder. 2016. Intratumoral infection with murine cytomegalovirus synergizes with PD-L1 blockade to clear melanoma lesions and induce long-term immunity. Mol. Ther. 24: 1444-1455.
25. Smith, C. J., S. Caldeira-Dantas, H. Turula, and C. M. Snyder. 2015. Murine CMV infection induces the continuous production of mucosal resident T cells. Cell Rep. 13: 1137-1148.
26. Smith, C. J., H. Turula, and C. M. Snyder. 2014. Systemic hematogenous maintenance of memory inflation by MCMV infection. PLoS Pathog. 10: e1004233.
27. Anderson, K. G., K. Mayer-Barber, H. Sung, L. Beura, B. R. James, J. J. Taylor, L. Qunaj, T. S. Griffith, V. Vezys, D. L. Barber, and D. Masopust. 2014. Intravascular staining for discrimination of vascular and tissue leukocytes. Nat. Protoc. 9: 209-222.
28. Cobbs, C. S., L. Harkins, M. Samanta, G. Y. Gillespie, S. Bharara, P. H. King, L. B. Nabors, C. G. Cobbs, and W. J. Britt. 2002. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62: 3347-3350.
29. Harkins, L., A. L. Volk, M. Samanta, I. Mikolaenko, W. J. Britt, K. I. Bland, and C. S. Cobbs. 2002. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360: 1557-1563.
30. Harkins, L. E., L. A. Matlaf, L. Soroceanu, K. Klemm, W. J. Britt, W. Wang, K. I. Bland, and C. S. Cobbs. 2010. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae 1: 8.
31. Samanta, M., L. Harkins, K. Klemm, W. J. Britt, and C. S. Cobbs. 2003. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J. Urol. 170: 998-1002.
32. Koldehoff, M., M. Lindemann, B. Opalka, S. Bauer, R. S. Ross, andA. H. Elmaagacli. 2015. Cytomegalovirus induces apoptosis in acute leukemia cells as a virusversus-leukemia function. Leuk. Lymphoma 56: 3189-3197.
33. Wu, Q. H., W. Trymbulak, R. J. Tatake, S. J. Forman, R. A. Zeff, and J. D. Shanley. 1994. Replication of human cytomegalovirus in cells deficient in beta 2-microglobulin gene expression. J. Gen. Virol. 75: 2755-2759.
34. Snyder, C. M., K. S. Cho, E. L. Bonnett, J. E. Allan, and A. B. Hill. 2011. Sustained CD8+ T cell memory inflation after infection with a single-cycle cytomegalovirus. PLoS Pathog. 7: e1002295.
35. Snyder, C. M., A. Loewendorf, E. L. Bonnett, M. Croft, C. A. Benedict, and A. B. Hill. 2009. CD4+ T cell help has an epitope-dependent impact on CD8+ T cell memory inflation during murine cytomegalovirus infection. J. Immunol. 183: 3932-3941.
36. Quinn, M., H. Turula, M. Tandon, B. Deslouches, T. Moghbeli, and C. M. Snyder. 2015. Memory T cells specific for murine cytomegalovirus re-emerge after multiple challenges and recapitulate immunity in various adoptive transfer scenarios. J. Immunol. 194: 1726-1736.
37. Amoah, S., R. D. Yammani, J. M. Grayson, and M. A. Alexander-Miller. 2012. Changes in functional but not structural avidity during differentiation of CD8+ effector cells in vivo after virus infection. J. Immunol. 189: 638-645.
38. Laouar, A., M. Manocha, V. Haridas, and N. Manjunath. 2008. Concurrent generation of effector and central memory CD8 T cells during vaccinia virus infection. PLoS One 3: e4089.
39. Xu, R., A. J. Johnson, D. Liggitt, and M. J. Bevan. 2004. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol. 172: 6265-6271.
40. Hertoghs, K. M., P. D. Moerland, A. van Stijn, E. B. Remmerswaal, S. L. Yong, P. J. van de Berg, S. M. van Ham, F. Baas, I. J. ten Berge, and R. A. van Lier. 2010. Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation. J. Clin. Invest. 120: 4077-4090.
41. Snyder, C. M., K. S. Cho, E. L. Bonnett, S. van Dommelen, G. R. Shellam, and A. B. Hill. 2008. Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity 29: 650-659.
42. Liang, S. C., Y. E. Latchman, J. E. Buhlmann, M. F. Tomczak, B. H. Horwitz, G. J. Freeman, and A. H. Sharpe. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33: 2706-2716.
43. Nielsen, C., L. Ohm-Laursen, T. Barington, S. Husby, and S. T. Lillevang. 2005. Alternative splice variants of the human PD-1 gene. Cell. Immunol. 235: 109-116.
44. Sierro, S., R. Rothkopf, and P. Klenerman. 2005. Evolution of diverse antiviral CD8+ T cell populations after murine cytomegalovirus infection. Eur. J. Immunol. 35: 1113-1123.
45. Yi, J. S., M. A. Cox, and A. J. Zajac. 2010. T-cell exhaustion: characteristics, causes and conversion. Immunology 129: 474-481.
46. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
47. Austin, J. W., P. Lu, P. Majumder, R. Ahmed, and J. M. Boss. 2014. STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. J. Immunol. 192: 4876-4886.
48. Blackburn, S. D., A. Crawford, H. Shin, A. Polley, G. J. Freeman, and E. J. Wherry. 2010. Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. J. Virol. 84: 2078-2089.
49. Zhang, Y., S. Kang, J. Shen, J. He, L. Jiang, W. Wang, Z. Guo, G. Peng, G. Chen, J. He, and W. Liang. 2015. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore) 94: e515.